Literature DB >> 22791285

Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells.

Bithi Chatterjee1, Anna Smed-Sörensen, Lillian Cohn, Cécile Chalouni, Richard Vandlen, Byoung-Chul Lee, Jenifer Widger, Tibor Keler, Lélia Delamarre, Ira Mellman.   

Abstract

Dendritic cells (DCs) can capture extracellular antigens and load resultant peptides on to MHC class I molecules, a process termed cross presentation. The mechanisms of cross presentation remain incompletely understood, particularly in primary human DCs. One unknown is the extent to which antigen delivery to distinct endocytic compartments determines cross presentation efficiency, possibly by influencing antigen egress to the cytosol. We addressed the problem directly and quantitatively by comparing the cross presentation of identical antigens conjugated with antibodies against different DC receptors that are targeted to early or late endosomes at distinct efficiencies. In human BDCA1+ and monocyte-derived DCs, CD40 and mannose receptor targeted antibody conjugates to early endosomes, whereas DEC205 targeted antigen primarily to late compartments. Surprisingly, the receptor least efficient at internalization, CD40, was the most efficient at cross presentation. This did not reflect DC activation by CD40, but rather its relatively poor uptake or intra-endosomal degradation compared with mannose receptor or DEC205. Thus, although both early and late endosomes appear to support cross presentation in human DCs, internalization efficiency, especially to late compartments, may be a negative predictor of activity when selecting receptors for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22791285     DOI: 10.1182/blood-2012-01-402370

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  95 in total

Review 1.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

2.  Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells.

Authors:  Kuan-Yin Shen; Ying-Chyi Song; I-Hua Chen; Chih-Hsiang Leng; Hsin-Wei Chen; Hui-Ju Li; Pele Chong; Shih-Jen Liu
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

Review 3.  The ins and outs of MHC class II-mediated antigen processing and presentation.

Authors:  Paul A Roche; Kazuyuki Furuta
Journal:  Nat Rev Immunol       Date:  2015-02-27       Impact factor: 53.106

Review 4.  Controlling immune responses by targeting antigens to dendritic cell subsets and B cells.

Authors:  Craig P Chappell; Natalia V Giltiay; Christiane Dresch; Edward A Clark
Journal:  Int Immunol       Date:  2013-11-27       Impact factor: 4.823

Review 5.  Pancreatic cancer, treatment options, and GI-4000.

Authors:  Marion L Hartley; Najeebah A Bade; Petra A Prins; Leonel Ampie; John L Marshall
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 6.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

Review 7.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

8.  Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition.

Authors:  Kirsteen M Tullett; Ingrid M Leal Rojas; Yoshihito Minoda; Peck S Tan; Jian-Guo Zhang; Corey Smith; Rajiv Khanna; Ken Shortman; Irina Caminschi; Mireille H Lahoud; Kristen J Radford
Journal:  JCI Insight       Date:  2016-05-19

9.  TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Qi Wang; Guangming Li; Riddhima Banga; Jianping Ma; Haisheng Yu; Fumihiko Yasui; Zheng Zhang; Giuseppe Pantaleo; Matthieu Perreau; Sandra Zurawski; Gerard Zurawski; Yves Levy; Lishan Su
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

10.  Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells.

Authors:  Anne-Laure Flamar; Yaming Xue; Sandra M Zurawski; Monica Montes; Bryan King; Louis Sloan; SangKon Oh; Jacques Banchereau; Yves Levy; Gerard Zurawski
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.